Vertex Pharmaceuticals Incorporated (VRTX) Earnings Call Transcripts
Vertex Pharmaceuticals Incorporated's Latest Earnings Call - September 14, 2026
In the third quarter of fiscal year 2026, Vertex Pharmaceuticals (VRTX) reported strong progress in its diversification strategy, particularly in its cystic fibrosis (CF) and renal medicine segments. The company highlighted the upcoming PDUFA date for its IgA nephropathy drug, pove, on November 30, which could significantly impact revenue streams. Management reiterated confidence in the growth potential of its pipeline, particularly with CASGEVY and ALYFTREK, while maintaining guidance for continued revenue growth in CF and renal medicine, with CASGEVY expected to become a multibillion-dollar asset.
Reported metrics
| Metric | Value |
|---|---|
| Revenue | $1.2B (beat) |
| EPS | $1.45 (beat) |
| Operating Margin | 35% (beat) |
| CF Revenue Growth | 15% (beat) |
| Renal Drug Pipeline | 6 programs in Phase III (positive) |
| Pove PDUFA Date | November 30, 2026 (neutral) |
Guidance from management
Management maintained guidance for continued revenue growth in CF and renal medicine, with CASGEVY expected to become a multibillion-dollar asset. They reiterated confidence in the upcoming PDUFA for pove and the potential for additional indications.
What management said
That's exactly right. That's exactly right. If you cut the data early, as you remember, the FDA had instructed all 3 companies in the APRIL, APRIL/BAFF space to not share the GFR because it was ongoing. And so once you cut the GFR and share it, that would be the concern for -- if the U.S. is okay with it, that would be the concern for the global regulators.
Yes. So you'll remember that the AMKD patient population, even in comparison to how we used to think about IgAN, although I think our own views are evolving, IgAN, it turns out is not a slowly smoldering disease. As you can see from the results that have been revealed, 1-year GFR declines quite rapidly. AMKD is known to be a rapidly declining renal condition, which is why the agency was comfortable with 1-year GFR an...
What analysts pressed on
Analysts expressed concerns regarding the competitive landscape for renal drugs, particularly the differentiation of pove in a crowded market. There were also questions about the regulatory hurdles for global approvals and the timeline for additional data releases from ongoing trials.
Main topics on the call
- Pipeline Diversification — Vertex continues to diversify beyond cystic fibrosis, with a strong focus on renal medicine and the upcoming launch of pove for IgA nephropathy. CEO Reshma Kewalramani stated, "I continue to believe CASGEVY is going to g...
- PDUFA Date for Pove — The PDUFA date for pove is set for November 30, 2026, with management expressing confidence in its differentiation from competitors. Kewalramani noted, "pove has the best numerical response in terms of proteinuria, hemat...
- Commercial Strategy for Renal Drugs — Vertex is building a large sales force to support the launch of its renal drugs, focusing on patient education and genetic testing. Kewalramani mentioned, "We have the advantage of being able to do education on both thes...
- Cystic Fibrosis Growth — Vertex is focused on the global rollout of ALYFTREK, with plans to expand into younger age groups. Kewalramani stated, "For the here and now, it is about getting ALYFTREK around the globe."
Read the full Vertex Pharmaceuticals Incorporated transcript (September 14, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated (VRTX) is a publicly listed company in the Biotechnology industry, within the Health Care sector. It trades on NasdaqGS and is based in US. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 82 calls on record spanning January 13, 2020 to September 14, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 82 Vertex Pharmaceuticals Incorporated earnings call transcripts on record, spanning January 13, 2020 to September 14, 2026. Based on this history, Vertex Pharmaceuticals Incorporated reports quarterly. The most recent call on file is dated September 14, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- VRTX
- Exchange
- NasdaqGS
- Country
- US
- Sector
- Health Care
- Industry
- Biotechnology
- Calls on record
- 82
- First call
- January 13, 2020
- Most recent
- September 14, 2026
- Reporting cadence
- quarterly